Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China

Open Access

Peer-reviewed

Research Article

Mehlika Toy ,

* E-mail: mtoy@stanford.edu

Affiliation Asian Liver Center, Department of Surgery, Stanford University School of Medicine, Stanford, CA, 94305, United States of America
⨯
David W. Hutton,

Affiliation Department of Health Management and Policy, University of Michigan, Ann Arbor, MI, 48109, United States of America
⨯
Samuel K. So

Affiliation Asian Liver Center, Department of Surgery, Stanford University School of Medicine, Stanford, CA, 94305, United States of America
⨯

Reader Comments (0)

Cirrhosis
Is the Subject Area "Cirrhosis" applicable to this article?

Thanks for your feedback.
Antiviral therapy
Is the Subject Area "Antiviral therapy" applicable to this article?

Thanks for your feedback.
Hepatitis B
Is the Subject Area "Hepatitis B" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.
Hepatocellular carcinoma
Is the Subject Area "Hepatocellular carcinoma" applicable to this article?

Thanks for your feedback.
China
Is the Subject Area "China" applicable to this article?

Thanks for your feedback.
Cost-effectiveness analysis
Is the Subject Area "Cost-effectiveness analysis" applicable to this article?

Thanks for your feedback.
Chronic hepatitis
Is the Subject Area "Chronic hepatitis" applicable to this article?

Thanks for your feedback.